Anne-Marie S. Duliege
Direktor/Vorstandsmitglied bei California Institute for Regenerative Medicine
Profil
Anne-Marie S.
Duliege is currently the Director at the California Institute for Regenerative Medicine since 2012.
She is also an Independent Director at Fe Pharmaceuticals (Canada), Inc. since 2020 and a Director at Fe Pharmaceuticals, Inc. Additionally, she has held former positions as the Senior Medical Director at Chiron Corp.
from 1992 to 2004, Director at The Bay Area Bioscience Association, Chief Medical Officer & Executive Vice President at Rigel Pharmaceuticals, Inc. from 2016 to 2019, Chief Strategic Development Officer & Executive VP at ChemoCentryx, Inc., and Chief Medical Officer at Affymax, Inc. from 2004 to 2013.
She is currently serving as the Chief Medical Officer at Pancreatic Cancer Action Network, Inc. from 2020 to 2024.
Dr. Duliege holds a graduate degree from Harvard T.H.
Chan School of Public Health and a doctorate degree from Université de Paris 5 René Descartes.
Aktive Positionen von Anne-Marie S. Duliege
| Unternehmen | Position | Beginn |
|---|---|---|
| California Institute for Regenerative Medicine | Direktor/Vorstandsmitglied | 01.10.2012 |
Fe Pharmaceuticals, Inc.
 Fe Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fe Pharmaceuticals, Inc. is a company based in San Diego, CA. Fe Pharmaceuticals, Inc. was founded by Bruce Holbein and is currently led by CEO Michael J. Weickert. | Direktor/Vorstandsmitglied | - |
Fe Pharmaceuticals (Canada), Inc.
 Fe Pharmaceuticals (Canada), Inc. Pharmaceuticals: MajorHealth Technology Fe Pharmaceuticals (Canada), Inc. operates as a research institution. It offers indication & treatment challenge, technical innovation and market services. The company was founded by William M. Cheliak and Bruce Holbein and is headquartered in Halifax, Canada. | Direktor/Vorstandsmitglied | 01.09.2020 |
Ehemalige bekannte Positionen von Anne-Marie S. Duliege
| Unternehmen | Position | Ende |
|---|---|---|
Pancreatic Cancer Action Network, Inc.
 Pancreatic Cancer Action Network, Inc. Medical/Nursing ServicesHealth Services Pancreatic Cancer Action Network, Inc. engages in the research, clinical initiatives, patient services, and advocacy for pancreatic cancer. The company was founded in 1999 and is headquartered in Manhattan Beach, CA. | Technik-/Wissenschafts-/F&E-Leiter | 02.04.2024 |
| RIGEL PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.08.2019 |
| AFFYMAX, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2013 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2004 |
| The Bay Area Bioscience Association | Direktor/Vorstandsmitglied | - |
Ausbildung von Anne-Marie S. Duliege
| Harvard T.H. Chan School of Public Health | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| AFFYMAX, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
| California Institute for Regenerative Medicine | Government |
| The Bay Area Bioscience Association | Health Technology |
Pancreatic Cancer Action Network, Inc.
Pancreatic Cancer Action Network, Inc. Medical/Nursing ServicesHealth Services Pancreatic Cancer Action Network, Inc. engages in the research, clinical initiatives, patient services, and advocacy for pancreatic cancer. The company was founded in 1999 and is headquartered in Manhattan Beach, CA. | Health Services |
| Université de Paris 5 René Descartes | Consumer Services |
Fe Pharmaceuticals (Canada), Inc.
Fe Pharmaceuticals (Canada), Inc. Pharmaceuticals: MajorHealth Technology Fe Pharmaceuticals (Canada), Inc. operates as a research institution. It offers indication & treatment challenge, technical innovation and market services. The company was founded by William M. Cheliak and Bruce Holbein and is headquartered in Halifax, Canada. | Health Technology |
Fe Pharmaceuticals, Inc.
Fe Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fe Pharmaceuticals, Inc. is a company based in San Diego, CA. Fe Pharmaceuticals, Inc. was founded by Bruce Holbein and is currently led by CEO Michael J. Weickert. | Health Technology |
